Sulfasalazine Modifies Metabolic Profiles and Enhances Cisplatin Chemosensitivity on Cholangiocarcinoma Cells in in vitro and in vivo models
Abstract Background: Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9 expressed cancer stem like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy. A recent report revealed high levels of CD44v9 positive cells in CCA patients. Therefore, a combination of drugs could prove a suitable strategy for CCA treatment via individual metabolic profiling. Methods: We examined the effect of xCT-targeted CD44v9-CSCs using sulfasalazine combined with cisplatin (CIS) or gemcitabine in CCA in vitro and in vivo model and did NMR-based metabolomics of xenograft mice tumor tissues. Results: Our findings suggest that combined SSZ and CIS leads to a higher inhibition of cell proliferation and induction of cell death than CIS alone in both in vitro and in vivo models. Xenograft mice showed that the CD44v9-CSC marker and CK-19-CCA proliferative marker were reduced in the combination treatment. Interestingly, different metabolic signatures and the significant metabolites were observed in the drug treated group compared with the control group that revealed the cancer suppression mechanisms. Conclusions: Taken together, SSZ could improve CCA therapy by sensitization to CIS through killing CD44v9-positive cells and modifying the metabolic pathways, in particular tryptophan degradation (i.e. kynurenine pathway, serotonin pathway) and nucleic acid metabolism..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
ResearchSquare.com - (2020) vom: 03. Sept. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thanee, Malinee [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-31522/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034593039 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034593039 | ||
| 003 | DE-627 | ||
| 005 | 20230429194541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-31522/v1 |2 doi | |
| 035 | |a (DE-627)XRA034593039 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-31522/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Thanee, Malinee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sulfasalazine Modifies Metabolic Profiles and Enhances Cisplatin Chemosensitivity on Cholangiocarcinoma Cells in in vitro and in vivo models |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9 expressed cancer stem like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy. A recent report revealed high levels of CD44v9 positive cells in CCA patients. Therefore, a combination of drugs could prove a suitable strategy for CCA treatment via individual metabolic profiling. Methods: We examined the effect of xCT-targeted CD44v9-CSCs using sulfasalazine combined with cisplatin (CIS) or gemcitabine in CCA in vitro and in vivo model and did NMR-based metabolomics of xenograft mice tumor tissues. Results: Our findings suggest that combined SSZ and CIS leads to a higher inhibition of cell proliferation and induction of cell death than CIS alone in both in vitro and in vivo models. Xenograft mice showed that the CD44v9-CSC marker and CK-19-CCA proliferative marker were reduced in the combination treatment. Interestingly, different metabolic signatures and the significant metabolites were observed in the drug treated group compared with the control group that revealed the cancer suppression mechanisms. Conclusions: Taken together, SSZ could improve CCA therapy by sensitization to CIS through killing CD44v9-positive cells and modifying the metabolic pathways, in particular tryptophan degradation (i.e. kynurenine pathway, serotonin pathway) and nucleic acid metabolism. | ||
| 700 | 1 | |a Padthaisong, Sureerat |e verfasserin |4 aut | |
| 700 | 1 | |a Suksawat, Manida |e verfasserin |4 aut | |
| 700 | 1 | |a Dokduang, Hasaya |e verfasserin |4 aut | |
| 700 | 1 | |a Phetcharaburanin, Jutarop |e verfasserin |4 aut | |
| 700 | 1 | |a Klanrit, Poramate |e verfasserin |4 aut | |
| 700 | 1 | |a Titapun, Attapol |e verfasserin |4 aut | |
| 700 | 1 | |a Namwat, Nisana |e verfasserin |4 aut | |
| 700 | 1 | |a ngiamwibool, Prakasit Sa- |e verfasserin |4 aut | |
| 700 | 1 | |a Khuntikeo, Narong |e verfasserin |4 aut | |
| 700 | 1 | |a Saya, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Loilome, Watcharin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2020) vom: 03. Sept. |
| 773 | 1 | 8 | |g year:2020 |g day:03 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-31522/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 03 |c 09 | ||
| 953 | |2 045F |a 570 | ||